Hands are one of the most socially and functionally significant organs in the human body. Touching, greeting, and working are primary social functions typically carried out by hands. Therefore, their effectiveness and appearance hold great importance for people. It is not surprising that hand diseases can compromise many aspects of daily life, significantly impacting overall quality of life.
Chronic hand eczema (CHE) is a common inflammatory skin condition that significantly impacts the quality of life. From work-related disabilities to social embarrassment, pain, and financial costs, the burden on society is substantial.
CHE is one of the most common occupational diseases, often leading to sick leave. Some reviews have estimated the economic burden of CHE, which includes costs for prescriptions, medications, laboratory exams, and productivity losses. This burden is likely underestimated, as it appears to affect approximately 5–10% of the population, with a similar prevalence among adolescents and adults. Skin examination may reveal a wide range of clinical manifestations characterized by erythema, vesicles, pustules, scales, fissures, and hyperkeratosis. The main thing is that eczema causes a lot of suffering to the patient, the affected areas are very itchy, up to the point of pain, they do not allow to sleep at night and work fully during the day. Often, eczema and skin atrophy are the first manifestations of venous insufficiency of the lower extremities, against which venous ulcers may later appear.
Chronic venous insufficiency (CVI) is a common pathology affecting thousands of individuals worldwide. According to the Clinical, Etiological, Anatomical, and Pathophysiological classification, reliable and reproducible grading of the severity of venous insufficiency enables one to choose the proper therapy. The development of CVI likely has several contributory factors, including a hereditary component and many risk factors. Venous dysfunction originates from venous hypertension and is associated with venous reflux due to poorly functioning or incompetent venous valves, which ultimately reduces venous return, leading to blood pooling, hypoxia, and inflammation.Valvular injury in the vein or vein occlusion occurs as well. Venous dysfunction causes high blood pressure within the veins, venous hypervolemia, swelling, lipodermatosclerosis, and, in severe cases, venous ulcers. CVI is widely associated with severe types of venous‐related complications, notably venous leg ulcers (VLU). VLU are more prevalent with higher age, which negatively affects their healing and recurrence. The majority (up to 80%) of patients develop a recurrence within 3 months. The goals of VLU treatment are to promote wound healing, reduce pain and edema, improve the quality of patient’s life and prevent ulcer recurrence. Standard evidence‐based care includes compression therapy and the use of adjunctive agents, surgery, has also been shown to improve ulcer healing and decrease the risk of recurrence.
Areсur Derma contains natural regenerative peptides in its composition, including, in particular,
apidaecins, rojal jelly proteins and abaecins, so it works effectively in have pronounced anti-infective and regenerating properties, therefore it effectively and naturally promotes the healing of eczema lesions, and also creates the necessary conditions for the revitalization of chronic venous ulcers. In eczema, Areсur Derma promotes cell regeneration at the site of erosive defects. Areсur Derma normalizes the metabolic process in the skin. By counteracting microbial biofilms in chronic ulcers, Areсur Derma promotes healing and prevents relapses.
For effective healing of eczema and trophic ulcers, it is sufficient to anoint the foci with Arecur 3-4 times a day for 10-14 days. If necessary, treatment can be extended, since Arecur Derma has no clinically proven allergic reactions and toxic complications over many years of use in patients.